Literature DB >> 26631948

Analysis of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours.

M Takanosu1, S Amano2, Y Kagawa2.   

Abstract

The aim of this study was to determine the type and frequency of c-KIT exon 11 mutations in canine gastrointestinal stromal tumours (GISTs) and investigate the association between the c-KIT mutation status and KIT immunohistochemical staining pattern. Mutations in exon 11 of c-KIT were examined in 46 formalin-fixed paraffin-embedded canine GISTs using PCR of genomic DNA and reverse transcription-PCR (RT-PCR) of cDNA. Exon 11 c-KIT mutations were detected in 15/46 (32.6%) cases by conventional PCR and 34/46 (73.9%) cases by RT-PCR; the mutation detection rate was significantly higher for RT-PCR (P = 0.004, Fisher's exact test). Ten different mutations, including deletion, internal tandem duplication and point mutations, were identified by RT-PCR. Immunohistochemistry was performed using an anti-KIT antibody; diffuse KIT staining was detected in the tumour cell cytoplasm in 32/46 (69.6%) cases and partial or stippled cytoplasmic staining of KIT was observed in 14/46 (30.4%) cases. Neither pattern was significantly associated with c-KIT exon 11 mutation status (P = 1.000, chi-square test). These data indicate that c-KIT exon 11 mutations occur frequently in canine GISTs, similar to human GISTs; however, there is no association between c-KIT mutations and the KIT expression pattern in canine GISTs. This study suggests that RT-PCR is more sensitive than conventional PCR for the detection of c-KIT mutations in canine GISTs.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Canine; Gastrointestinal stromal tumours; Immunohistochemistry; Mutation; c-KIT

Mesh:

Substances:

Year:  2015        PMID: 26631948     DOI: 10.1016/j.tvjl.2015.10.051

Source DB:  PubMed          Journal:  Vet J        ISSN: 1090-0233            Impact factor:   2.688


  3 in total

1.  The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.

Authors:  Fabio Gentilini; Maria Elena Turba; Claire Dally; Masamine Takanosu; Sena Kurita; Makoto Bonkobara
Journal:  BMC Vet Res       Date:  2020-02-19       Impact factor: 2.741

2.  Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs).

Authors:  Maria Morini; Fabio Gentilini; Maria Elena Turba; Francesca Gobbo; Luciana Mandrioli; Giuliano Bettini
Journal:  Vet Sci       Date:  2022-07-21

3.  Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.

Authors:  Erika P Berger; Chad M Johannes; Albert E Jergens; Karin Allenspach; Barbara E Powers; Yingzhou Du; Jonathan P Mochel; Leslie E Fox; Margaret L Musser
Journal:  J Vet Intern Med       Date:  2018-10-11       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.